The accuracy of circulating microRNA-21 in the diagnosis of colorectal cancer: A systematic review and meta-analysis

Colorectal Disease

Volumn 17, Issue 5, 2015, Pages O100-O107

  Xu, F ^a   Xu, L ^a   Wang, M ^a   An, G ^a   Feng, G ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Colorectal cancer; Diagnosis; Meta analysis; MicroRNA 21

Indexed keywords

MICRORNA 21; TUMOR MARKER; MICRORNA; MIRN21 MICRORNA, HUMAN;

COCHRANE LIBRARY; COLORECTAL CANCER; DISEASE ASSOCIATION; EMBASE; HUMAN; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; COLORECTAL NEOPLASMS; ODDS RATIO; RECEIVER OPERATING CHARACTERISTIC;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; HUMANS; MICRORNAS; ODDS RATIO; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84928169504     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12917     Document Type: Review

References (41)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64: 104-17.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
3. Jemal A, Clegg LX, Ward E et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004; 101: 3-27.
4. Stracci F, Zorzi M, Grazzini G. Colorectal cancer screening: tests, strategies, and perspectives. Front Public Health 2014; 2: 210.
5. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-27.
6. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-55.
7. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
8. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12.
9. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids - the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011; 8: 467-77.
10. Li T, Leong MH, Harms B, Kennedy G, Chen L. MicroRNA-21 as a potential colon and rectal cancer biomarker. World J Gastroenterol 2013; 19: 5615-21.
11. Xia X, Yang B, Zhai X et al. Prognostic role of microRNA-21 in colorectal cancer: a meta-analysis. PLoS One 2013; 8: e80426.
12. Toiyama Y, Takahashi M, Hur K et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 2013; 105: 849-59.
13. Ogata-Kawata H, Izumiya M, Kurioka D et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One 2014; 9: e92921.
14. Faltejskova P, Besse A, Sevcikova S et al. Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. Int J Colorectal Dis 2012; 27: 1401-8.
15. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-8.
16. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
17. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31.
18. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 2009; 374: 609-19.
19. Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods. Arch Pathol Lab Med 1998; 122: 675-86.
20. Dinnes J, Deeks J, Kirby J, Roderick P. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 2005; 9: 1-113, iii.
21. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol 2012; 138: 1659-66.
22. Kanaan Z, Rai SN, Eichenberger MR et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 2012; 256: 544-51.
23. Liu GH, Zhou ZG, Chen R et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol 2013; 34: 2175-81.
24. Luo X, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS One 2013; 8: e62880.
25. Basati G, Emami Razavi A, Abdi S, Mirzaei A. Elevated level of microRNA-21 in the serum of patients with colorectal cancer. Med Oncol 2014; 31: 205.
26. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-4.
27. Wei J, Gao W, Zhu CJ et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 2011; 30: 407-14.
28. Tsujiura M, Ichikawa D, Komatsu S et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010; 102: 1174-9.
29. Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res 2010; 3: 28-47.
30. Yaman Agaoglu F, Kovancilar M, Dizdar Y et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 2011; 32: 583-8.
31. Bihrer V, Waidmann O, Friedrich-Rust M et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011; 6: e26971.
32. Komatsu S, Ichikawa D, Takeshita H et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 2011; 105: 104-11.
33. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003; 56: 1129-35.
34. Wang J, Huang SK, Zhao M et al. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One 2014; 9: e87451.
35. Asangani IA, Rasheed SA, Nikolova DA et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-36.
36. Xiong B, Cheng Y, Ma L, Zhang C. MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. Int J Oncol 2013; 42: 219-28.
37. Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007; 282: 14328-36.
38. Gabriely G, Wurdinger T, Kesari S et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 2008; 28: 5369-80.
39. Liu Z, Zhang Y, Niu Y et al. A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer. PLoS One 2014; 9: e103910.
40. Yang X, Zeng Z, Hou Y et al. MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: a systematic review and meta-analysis. PLoS One 2014; 9: e88745.
41. Wang Q, Huang Z, Ni S et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One 2012; 7: e44398.